Drug Profile
Research programme: Crohn's disease therapeutics - DBV Technologies/Icahn School of Medicine
Alternative Names: Crohn's disease therapy - DBV Technologies/Icahn School of MedicineLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator DBV Technologies; Icahn School of Medicine at Mount Sinai
- Developer DBV Technologies
- Class Proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Crohn's disease in France (Transdermal)
- 28 Mar 2018 No recent reports of development identified for preclinical development in Crohn's-disease in France (Transdermal, Patch)
- 13 Jun 2016 Pharmacodynamics data from a preclinical study released by DBV Technologies